DEA Extends Temporary Status of Benzimidazole-Opioids in Schedule I, Proposes Permanent Listings
The Drug Enforcement Administration is extending for one more year the temporary listing of three synthetic benzimidazole-opioid substances -- butonitazene, flunitazene and metodesnitazene -- in Schedule I of the Controlled Substances Act, it said in a notice released April 10.…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
The synthetic benzimidazole-opioids, first temporarily listed in 2022 (see 2204110029), will now remain listed in Schedule I until April 12, 2025. DEA also released a proposed rule to permanently list these synthetic benzimidazole-opioids in Schedule I, with comments due May 13. Substances may be temporarily listed under the CSA for three years.